16 September 2026 editorial review · Item
Selective JAK inhibitors (abrocitinib / ritlecitinib): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: JAKPOT current registry Sep 2 moves estimated primary completion to 30 October 2026 and final 30 October 2027; updated stale June timing. No posted T1D efficacy.
- Registry NCT05743244: ACTIVE_NOT_RECRUITING; updated 2026-09-02; enrollment 78 (ESTIMATED); primary completion 2026-10-30 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: 213871s000lbl.pdf.